A look back at the week's top stories.
Essentially no safe levels of toxic ‘forever chemicals’ found in many US water systems.
Results suggest the potential of this oral therapy to address the unmet clinical need for long-term medical treatment for endometriosis.
Evofem Biosciences, Inc. recently announced results of a post hoc analysis of the registrational Phase 3 AMPOWER trial, which investigated the ability of a contraceptive gel consisting of lactic acid, citric acid, and potassium bitartrate (Phexxi; Evofem) to prevent pregnancy.
Vaginal yeast infections were successfully treated with berberine, a biologically active herbal alkaloid, according to a study published in Frontiers in Pharmacology.
Using National Inpatient Sample data from a nearly 2 decade period, investigators detail the increased risk of cardiovascular complications among women with PCOS during delivery hospitalizations and predictors of this increased risk.
New research suggests cumulative exposure to PFAS could increase risk of incident hypertension by 71% among midlife women.
Major congenital malformations not linked to first trimester tetracycline use
November 20th 2024A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.
Read More
IUD placement within 48 hours nonsuperior vs 2 to 4 weeks after abortion
November 19th 2024A study reveals no significant difference in 6-month intrauterine device use between placements within 48 hours or 2 to 4 weeks after a second-trimester abortion, though earlier placement carries a higher expulsion risk.
Read More